Skip to main content

Sildenafil and cardiovascular events — drug interactions

  • Chapter
Sildenafil

Part of the book series: Milestones in Drug Therapy MDT ((MDT))

  • 355 Accesses

Abstract

The most common cause of erectile dysfunction (ED) is vascular endothelial dysfunction [1]. Cardiovascular diseases share the same risk factors as ED — smoking, hyperlipidaemia, diabetes and hypertension — and the coexistence of a cardiac problem may cause concern with regard to advising on the treatment of ED (Fig. 1). This concern has increased with the realisation that ED is a marker for previously undetected coronary artery disease and the casual use of sildenafil without proper assessment — so-called ‘Internet sex’ — precipitating acute cardiac events [2, 3].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Solomon H, Man JW, Jackson G (2003) Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart 89: 251–253

    Article  PubMed  CAS  Google Scholar 

  2. Kirby M, Jackson G, Betteridge J, Friedli K (2001) Is erectile dysfunction a marker for cardiovascular disease? Int J Clin Pract 55: 614–618

    PubMed  CAS  Google Scholar 

  3. Solomon H, Man J, Jackson G (2002) Viagra on the Internet — Unsafe Sexual Practice. Int J Clin Pract 56: 403–404

    PubMed  CAS  Google Scholar 

  4. Yusuf S (2002) Two decades of progress in preventing vascular disease. Lancet 360: 2–3

    Article  PubMed  Google Scholar 

  5. Gillies HC, Roblin D, Jackson G (2002) Coronary and systemic haemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease. Int J Cardiol 86: 131–141

    Article  PubMed  Google Scholar 

  6. Jackson G, Betteridge J, Dean J, Eardley I, Hall R, Holdright D, Holmes S, Kirby M, Riley A, Sever P (2002) A systematic approach to erectile dysfunction in the cardiovascular patient: a consensus statement — update 2002. Int J Clin Pract 56: 663–671

    PubMed  CAS  Google Scholar 

  7. Kloner RA, Hutter AM, Emmick JT, Mitchell MI, Denne J, Jackson G (2003) Time course of interaction between tadalafil and nitrates. J Am Coll Cardiol 42: 1855–1860

    Article  PubMed  CAS  Google Scholar 

  8. Webb DJ, Freestone S, Allen MJ, Muirhead GJ (1999) Sildenafil citrate and blood pressure lowering drugs: results of drug interaction studies with an organic nitrate and calcium antagonist. Am J Cardiol 83: 21C–28C

    Article  PubMed  CAS  Google Scholar 

  9. Webb DJ, Muirhead GJ, Wulff M, Sutton JA, Levi R, Dinsmore WW (2000) Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol 36: 25–31

    Article  PubMed  CAS  Google Scholar 

  10. Stief C, Porst H, Saenz De Tejada I, Ulbrich E, Beneke M; Vardenafil Study Group (2004) Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction. Int J Clin Pract 58: 230–239

    Article  PubMed  CAS  Google Scholar 

  11. Jackson G, Cooper A, McGing E, Martin E (2003) Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5 inhibitor use in cardiac patients with erectile dysfunction. Int J Imp Res 15 (Suppl 6): 520 (Abst)

    Google Scholar 

  12. Martin E, Cooper A, McGing E, Jackson G (2003) Carrying short acting nitrates is not a contraindication to PDE5 inhibition. Int J Imp Res 15 (Suppl 6): 520 (Abst)

    Google Scholar 

  13. Jackson G, Bedding A, Emmich J (2003) Interaction between tadalafil and two alpha blockers: doxazosin and tamsulosin. Int J Imp Res 15 (Suppl 6): 560 (Abst)

    Google Scholar 

  14. Kloner RA (2004) Cardiovascular Safety of Phosphodiesterase-5 Inhibitors. In: RA Kloner (ed): Heart Disease and Erectile Dysfunction. Humana Press, New Jersey, 139–161

    Chapter  Google Scholar 

  15. Jackson G (2002) Phosphodiesterase type 5 inhibition in cardiovascular disease: experimental models and potential clinical applications. Eur Heart J 4, Supplements (Suppl H): H19–H23

    CAS  Google Scholar 

  16. Langtry HD, Markham A (1999) Sildenafil: A review of its use in erectile dysfunction. Drugs 57: 967–989

    Article  PubMed  CAS  Google Scholar 

  17. Jackson G (2003) PDE5 inhibitors: looking beyond erectile dysfunction. Int J Clin Pract 57: 159–160

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Basel AG

About this chapter

Cite this chapter

Jackson, G. (2004). Sildenafil and cardiovascular events — drug interactions. In: Dunzendorfer, U. (eds) Sildenafil. Milestones in Drug Therapy MDT. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-7945-3_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-7945-3_10

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9631-3

  • Online ISBN: 978-3-0348-7945-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics